AKT1 and plasma cell myeloma: Further investigation revealed that the anticancer effects of diallyl thiosulfinate and dexamethasone co-treatment were due to the up-regulation of miR-127-3p and down-regulation of PI3K, p-mTOR, and p-Akt, resulting in the deactivation of the PI3K/AKT signaling pathway in multiple myeloma cells [85].